RBC Capital Maintains Outperform on Mind Medicine, Raises Price Target to $7
Portfolio Pulse from richadhand@benzinga.com
RBC Capital analyst Brian Abrahams has maintained an 'Outperform' rating on Mind Medicine (NASDAQ:MNMD) and raised the price target from $5 to $7.
August 04, 2023 | 3:51 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
RBC Capital's 'Outperform' rating on Mind Medicine (NASDAQ:MNMD) is maintained and the price target is raised from $5 to $7.
The maintained 'Outperform' rating and increased price target by RBC Capital indicates a positive outlook for Mind Medicine. This could potentially attract more investors, driving the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100